STIFEL 2026: REGENXBIO will have its pivotal studies for wet AMD read out before the end of the year - combined, they are the largest study of a gene therapy ever
CEO Curran Simpson sets the table for the readouts and describes what he believes they need to show in order to succeed. Plus, updates on the DMD program and RGX-121.
Coverage brought to you by










.png)
